Arcutis to raise $150M in public stock offering
Arcutis Biotherapeutics, a Westlake Village-based company developing drugs for immune dermatological conditions, plans to raise $150 million through a public offering of additional shares of common stock. Arcutis announced the pricing of those shares on Aug. 2, at $20 per share. Shares of Arcutis closed at $19.50 that day and then shot up 17% on Read More →
Arcutis reports Q1 loss, progress toward product launch
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Arcutis share up after earnings report; company reports mounting losses but progress toward FDA approval
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Tech Briefcase: Interlink expands in Scotland; Arcutis gets patent; Marcus & Millichap hacked
Interlink Electronics, an Irvine-based sensor manufacturer with its research and development hub in Camarillo, announced Sept. 23 that it plans to expand its European presence with a new engineering team in Scotland. The new team will start with five engineers and will be located near the University of Strathclyde in Glasgow. To support the group, Read More →
Arcutis ends phase 2 trials on potential skin treatment
Shares of Westlake Village-based Arcutis Biotherapeutics dropped by as much as 5% during the trading day July 1, after the biotech company terminated phase 2 trials for a potential treatment. Arcutis, a biotech company focused on creating dermatology treatments, has announced July that it had terminated phase 2a and 2b trials for evaluating ARQ-252, a Read More →
Arcutis shares down after earnings report
Westlake Village-based Arcutis Biotherapeutics suffered a net loss in the first quarter of fiscal year 2021, but continues to hold a strong financial position with $446.5 million in assets. According to earnings released May 4, Arcutis lost $36 million in the first quarter, or 76 cents per share, compared to a loss of $28 million, Read More →
Arcutis shares flat on earnings report
Arcutis Biotherapeutics saw a steep rise in operating expenses resulting in a 183% increase in net loss compared to the previous year when the company revealed its fourth quarter and full-year financial results on Feb. 16. However, the Westlake Village biotech company is still in high spirits, as the company is in a “strong financial Read More →
